AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 123 min read$JNJ

Johnson & Johnson's Tremfya Shows Promising Long-Term Remission

Johnson & Johnson (JNJ) reported that its drug Tremfya achieved 94% clinical remission in Crohn’s disease patients over three years in phase 3 trials. JNJ has a 1.95% dividend yield, 55% payout ratio, and 4.9% 3-year dividend growth. The stock is 35.7% above its GF Value of $194.33, trading at $263.73. JNJ has a GF Score of 83, indicating strong financial health, but insiders have been net sellers.

Original reporting
gurufocus.com
Published Oct 12, 2026, 9:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 10:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The data could improve JNJ's growth outlook and support its immunology franchise.

02

Market read

First disclosure of pivotal trial results; likely to move JNJ stock and affect the broader pharma sector.

03

What to watch

Insider selling and modest dividend yield could temper upside.

Relevance 7/10Novelty 9/10Timing: today, following the Oct 12 release

Background

Johnson & Johnson announced new long-term remission data for its Crohn's disease drug Tremfya.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Phase 3 GALAXI 2 and GALAXI 3 trials showed Tremfya achieving up to 94% remission over three years, a first-time disclosure.

Expected impact

upward pressure as the market prices in the efficacy data

Evidence & confidence

Clinical success for a major immunology asset is material for a large-cap pharma and often triggers buying.

Market effects

Sector

Strengthens the immunology segment and may lift peers with similar pipelines.

Regional

U.S. healthcare sector could see modest gains.

Global

Highlights continued innovation in global biotech, may influence investor allocations to pharma.

Counterpoint

What could challenge this read

Valuation remains high; the stock may be overbought despite the data.

Key entities

  • company
    Johnson & Johnson

    US-listed healthcare conglomerate (ticker JNJ).

  • drug
    Tremfya (guselkumab)

    JNJ's immunology product showing high remission rates.

Read at source← All news

StoryJohnson & Johnson reports three‑year TREMFYA efficacy and safety data in Crohn’s disease

Also covered by

1 outlet

Related articles

OCT 12
$JNJMedAI 9/10

Johnson & Johnson Reports Strong Three-Year Data for TREMFYA in

Johnson & Johnson (JNJ) reported three-year data from Phase 3 trials showing sustained effectiveness and safety of TREMFYA for Crohn’s disease. The stock offers a 1.95% dividend yield with a 55% payout ratio and a 4.9% 3-year growth rate, but is 35.7% overvalued relative to its GF Value™ of $194.33. JNJ has a strong GF Score™ of 83/100, with notable insider selling and mixed guru activity.

gurufocus.com2 min
OCT 12
$JNJHigh

Johnson & Johnson Announces New Three-Year Data From Phase 3 GALAXI 2 And 3 Studies Showing Durable Efficacy And A Consistent Safety Profile for TREMFYA

Johnson & Johnson presented three-year data from Phase 3 GALAXI 2 and 3 studies, showing durable efficacy and consistent safety for TREMFYA in Crohn's disease. Results indicate high rates of clinical and endoscopic remission for both dosing regimens. TREMFYA is approved for Crohn's disease and other inflammatory conditions.

marketscreener.com2 min
OCT 12
$JNJMed

Johnson & Johnson Announces New Phase 3 Data Showing Consistent Combined Fistula Remission Outcomes With TREMFYA Across Clinically Important Subgroups Of Adults With Crohn's Disease With Perianal Fistula

Johnson & Johnson reported Phase 3 data showing TREMFYA achieved 28% and 27% combined fistula remission in Crohn's disease patients, vs. 10% for placebo. Subgroup analyses showed consistent results across different patient types. The study was presented at the ACG 2026 meeting.

marketscreener.com2 min
OCT 12
$JNJMedAI 9/10

J&J’s Tremfya shows fistula remission in Crohn’s subgroups

Johnson & Johnson (JNJ) reported Phase 3 data showing Tremfya achieved 28% and 27% fistula remission in Crohn's patients at Week 24, versus 10% for placebo. Subgroup analyses showed higher remission rates in specific patient groups. Tremfya is approved for Crohn's disease in the U.S. The data was presented at the American College of Gastroenterology 2026 meeting.

investing.com2 min
OCT 12
$JNJMed

J&J reports three-year tremfya data for Crohn’s disease

Johnson & Johnson (JNJ) reported three-year data from its Phase 3 GALAXI 2 and 3 studies on TREMFYA for Crohn's disease. 94% and 91% of patients achieved clinical remission with 100 mg and 200 mg doses, respectively. 52% and 61% achieved endoscopic remission. 74% remained on treatment for three years. Data was presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.

investing.com2 min